Study S003338

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VCT220 Tablets in Overweight or Obese Participants

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06939296
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 840
Start: 2024-12-24
Primary completion: 2025-11-25
Lead sponsor: Vincentage Pharma Co., Ltd
Conditions: Obesity; Overweight
Interventions: DRUG:VCT220; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Percentage change from baseline in body weight [From baseline to week 34]
The proportion of subjects with a body weight reduction ≥5% from baseline [From baseline to week 34]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.